Growth Metrics

BioNexus Gene Lab (BGLC) Share-based Compensation (2023 - 2025)

BioNexus Gene Lab recorded quarterly Share-based Compensation of $794770.0 in Q4 2025, up 983.07% quarter-over-quarter from -$90001.0 in Q4 2023.

BioNexus Gene Lab's Share-based Compensation history runs 2 years deep, the most recent figure standing at $794770.0 for Q4 2025.

  • In Q4 2025, Share-based Compensation changed N/A year-over-year to $794770.0; the TTM figure through Dec 2025 stood at $704769.0 (changed N/A YoY), while the FY2025 annual figure was $794770.0, up 463.67% from the prior year.
  • Share-based Compensation came in at $794770.0 for Q4 2025 at BioNexus Gene Lab, up from -$90001.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $794770.0 in Q4 2025 to a low of -$90001.0 in Q4 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Share-based Compensation (Qtr)
1 Linde 230.79 Bn 226.84 Bn 4.26 Bn 41.00 Mn
2 Chemical & Mining Co Of Chile 127.66 Bn 124.93 Bn 778.60 Mn -
3 Sherwin Williams 72.51 Bn 72.30 Bn 2.78 Bn 29.50 Mn
4 Ecolab 70.96 Bn 70.34 Bn 1.85 Bn 27.10 Mn
5 Air Products & Chemicals 62.15 Bn 63.70 Bn 987.40 Mn 15.90 Mn
6 Ppg Industries 25.04 Bn 23.57 Bn 1.66 Bn 11.00 Mn
7 LyondellBasell Industries 21.62 Bn 21.73 Bn 701.00 Mn 47.00 Mn
8 Albemarle 20.26 Bn 19.42 Bn 500.97 Mn 7.88 Mn
9 DuPont de Nemours 19.45 Bn 19.56 Bn 602.00 Mn 13.00 Mn
10 BioNexus Gene Lab 5.34 Mn 1.38 Mn -790.00 -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 794,770.00
Dec 31, 2025 794,770.00
Dec 31, 2023 -90,001.00
Dec 31, 2023 -90,001.00